3D Bioprinting Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global 3D bioprinting market is experiencing robust growth, with its value expected to reach $2.6 billion in 2024 and surge further to $5.9 billion by 2031. This remarkable growth represents a compound annual growth rate (CAGR) of 12.4% during the forecast period from 2024 to 2031. The increasing demand for organ transplants, technological advancements, and growing academic interest are key drivers fueling this market expansion.

Demand from Healthcare Industry for 3D Bioprinting

In recent years, the healthcare sector has significantly increased its demand for 3D bioprinting solutions. These advanced technologies are employed in the development of organs and the construction of tissues, which are crucial for medical implants and research and development (R&D) activities related to drugs. The 3D bioprinting market is still at an embryonic stage but holds immense potential for generating human tissue replacements, marking a significant advancement in the medical field.

One of the primary applications of 3D bioprinting technology is in drug testing. The ability to test potential drug compounds on bioprinted tissues before using them on human beings accelerates the drug development process and enhances its accuracy and efficiency.

Growing Academic Interest in 3D Bioprinting

3D bioprinting has garnered substantial attention from academicians globally. Numerous researchers are launching start-up firms to commercialize this innovative technology. These start-ups are developing various products based on bioprinting technology, aiming to revolutionize the healthcare industry.

For instance, Aspect Biosystems is focusing on printing tissue models for toxicity testing, while TeViDo BioDevices is developing breast tissues. Similarly, SkinPrint is dedicated to creating human skin through 3D bioprinting. These advancements underline the diverse applications of 3D bioprinting technology and its potential to address critical healthcare needs.

North America: A Dominant Region

Geographically, North America is anticipated to dominate the global 3D bioprinting market in the coming years. The region's dominance can be attributed to the high number of target populations, the presence of key market players, and the availability of sophisticated healthcare infrastructure. Additionally, increased investments by regional players in R&D activities are expected to further propel market growth in North America.

Recent Market Developments

In March 2022, BICO Group AB (US) launched BIO CELLX, a novel system designed to automate the workflow of 3D cell culture using prevalidated protocols. This innovation represents a significant step forward in the commercialization of 3D bioprinting technology.

Competitive Landscape

The current market for 3D bioprinting comprises 14 industry-sponsored bioprinters focused on various commercial applications. Addressing the supply-demand gap for organ transplants remains an unmet need, with researchers aiming to create bioprinted organs for transplantation in the future. This goal underscores the potential of the 3D bioprinting market, which relies on biocompatible materials (bio-ink and bio-paper), software (CAD), and hardware (bioprinters).

The focus of the market is expected to shift from research to commercialization, with applications such as tissue engineering (skin and cartilage) and drug testing (skin and cartilage) gaining popularity. The early success of bioprinted organ transplants is anticipated to offer a substantial boost to the market, potentially transforming it into a multi-billion-dollar industry.

Aspect Biosystems aims to significantly reduce the cost and time required for drug development and testing, leading to treatments for currently incurable diseases and more affordable healthcare options. Other notable companies in the bioprinting market include SkinPrint, which is developing replacement skin for burn patients and individuals with skin disorders, and Advanced Biomatrix, 3D Biotek, 3D Systems, Avita Medical, and several others.

Institutional Support and Research Grants

To foster innovation in 3D bioprinting, the U.S. FDA has awarded a grant of $2.5 million to five research institutions for biomanufacturing research, including 3D bioprinting. The recipient institutions are Carnegie Mellon University, Harvard University, Georgia Institute of Technology, Rutgers University, and the Massachusetts Institute of Technology. These grants underscore the importance of collaborative efforts between institutions and industry players to advance the 3D bioprinting market.

Key Market Players Include

• Envisiontec, Inc.
• Precise Bio
• Organovo Holdings, Inc.
• Revotek Co., Ltd.
• Inventia Life Science PTY LTD
• Vivax Bio
• Poietis
• Allevi
• Biomedical K.K.
• Cellink Global
• Bioprinting Solutions

Global 3D Bioprinting Market Segmentation

By Component:

• 3D Bioprinters
• Bioinks

By Application:

• Research Applications
• Clinical Applications

By End User:

• Research Organization and Academic Institutes
• Biopharmaceutical Companies
• Hospitals

By Region:

• North America
• Europe
• Latin America
• East Asia
• The Middle East & Africa
• South Asia & Pacific

This product will be delivered within 1-3 business days.